| HOME >> MEDICINE >> TECHNOLOGY |
Future product milestones 29
Chapter 4 Company introduction 30
Key findings 30
Background 31
Key corporate developments 31
M&A history 31
Chapter 5 Company sales 34
Key findings 34
Prescription pharmaceutical sales and growth rate analysis, 2002-14 35
Product analysis 37
Therapy area analysis 44
Geographic analysis 46
Launch/core/expiry analysis 49
Molecule type analysis 54
Externalization analysis 56
Chapter 6 Company financials 59
Key findings 59
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 60
Operating costs and profit analysis 61
Chapter 7 Key products and competitors 67
Key findings 67
Overview 68
Infectious diseases 69
Cardiovascular 80
Chapter 8 Appendix 83
R&D pipeline 83
References 84
Abbreviations 84
About Datamonitor 86
Datamonitor consulting 86
Disclaimer 88
Table of tablesTable 1: Gilead - PharmaVitae forecasts at a glance 8
Table 2: Gilead's HIV franchise, 2008-14 ($m) 10
Table 3: Gilead key product developments, 2009 24
Table 4: Gilead product deals and alliances, 2009 25
Table 5: Gilead technology deals and alliances, 2009 26
Table 6: Gilead M&A activity, 2009 27
Table 7: Gilead company announcements, 2009 28
Table 8: Gilead future product milestones, 2009-11 29
Table 9: Gilead product portfolio overview ($m), 2002-08 39
Table 10: Gilead product portfolio overview ($m), 2008-14 41
Table 11: Gilead prescription pharmaceutical sales by therapy area ($m), 2008-14 45
Table 12: Gilead prescription ph
'/>"/>
| SOURCE Reportlinker Copyright©2009 PR Newswire. All rights reserved |